Compare Abeona Therapeutics Inc (ABEO) vs GXO Logistics Inc (GXO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs GXO Logistics Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while GXO Logistics Inc trades at $48.98 (market cap $5.89B). The key difference: GXO Logistics Inc is far larger — about 15.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | GXO | |
|---|---|---|
Market Cap | $373.32M | $5.89B |
Sector | Health | Industrials |
52-Week High | $7.23 | $65.59 |
52-Week Low | $4.17 | $45.52 |
Enterprise Value | $228.22M | $11.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
GXO trades at $51.16, down 1.52% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and a record sales pipeline of $2.7 billion highlight operational momentum. The company secured multiple long-term partnerships in Europe, reinforcing its contract logistics leadership.
Outlook remains positive with a consensus price target of $69.33, implying 35% upside. Risks include Amazon's market entry and retail sector exposure. Revenue growth and margin expansion in 2026 forecasts support a bullish case, though competition and macro pressures warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →
